Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

The lab's 25 or so full-time employees were put on administrative leave on March 27, forcing it to shut down operations.

The Centers for Disease Control and Prevention (CDC) reinstated more than 400 employees who had previously been laid off, the ...

INTRODUCTION Tuberculosis continues to be the leading cause of death from a single infectious disease agent among adults worldwide. 1 In 2022, tuberculosis was responsible for 1.3 million deaths and ...